Dima Sobko / Shutterstock.com
Australia’s government has said the period of data exclusivity available for biological drugs in the Trans-Pacific Partnership (TPP) will be five years, despite pressure from the US to extend it to 12.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
TPP; data exclusivity; biologics; pharmaceutical companies; Andrew Robb; BIO; biosimilars
